Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Panmure Upgrades Shire To Buy From Hold

Thu, 16th Oct 2014 08:36

LONDON (Alliance News) - The following UK shares received analyst recommendations Thursday morning:
----------
FTSE 100
----------
BERENBERG CUTS ROLLS-ROYCE PRICE TARGET TO 1160 (1216) PENCE - 'BUY'
----------
UBS RAISES ANTOFAGASTA TO 'NEUTRAL' ('SELL') - TARGET 710 PENCE
----------
UBS CUTS ANGLO AMERICAN PRICE TARGET TO 1450 (1700) PENCE - 'NEUTRAL'
----------
UBS CUTS BHP BILLITON PRICE TARGET TO 2100 (2300) PENCE - 'BUY'
----------
UBS CUTS RIO TINTO PRICE TARGET TO 3500 (3900) PENCE - 'BUY'
----------
GOLDMAN RAISES RIO TINTO PRICE TARGET TO 2600 (2550) PENCE - 'CONVICTION SELL LIST'
----------
UBS CUTS FRESNILLO PRICE TARGET TO 1000 (1050) PENCE - 'BUY'
----------
BARCLAYS RAISES ASTRAZENECA PRICE TARGET TO 4150 (4100) PENCE - 'EQUAL WEIGHT'
----------
TRADERS: MERRILL LYNCH ADDS ASTRAZENECA TO 'EUROPE 1 LIST'
----------
BARCLAYS CUTS GLAXOSMITHKLINE PRICE TARGET TO 1485 (1500) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES SHIRE PRICE TARGET TO 4100 (3900) PENCE - 'OVERWEIGHT'
----------
PANMURE RAISES SHIRE TO 'BUY' ('HOLD') - TARGET 4200 (5300) PENCE
----------
GOLDMAN CUTS BABCOCK INTERNATIONAL PRICE TARGET TO 1380 (1405) PENCE - 'BUY'
----------
CREDIT SUISSE CUTS ARM PRICE TARGET TO 1000 (1100) PENCE - 'OUTPERFORM'
----------
HSBC CUTS WPP PRICE TARGET TO 1540 (1600) PENCE - 'OVERWEIGHT'
----------
TRADERS: NUMIS RAISES WHITBREAD TO 'ADD' ('HOLD')
----------
Numis Cuts Diageo Price Target To 1,800p From 1,900p, Reiterates Hold
----------
FTSE 250
----------
UBS RAISES BELLWAY PRICE TARGET TO 1910 (1870) PENCE - 'BUY'
----------
UBS REMOVES FERREXPO FROM 'LEAST PREFERRED LIST' - 'SELL'
----------
UBS CUTS FERREXPO PRICE TARGET TO 80 (100) PENCE - 'SELL'
----------
UBS CUTS HOCHSCHILD MINING PRICE TARGET TO 135 (185) PENCE - 'NEUTRAL'
----------
UBS CUTS KAZAKHMYS PRICE TARGET TO 340 (370) PENCE - 'BUY'
----------
UBS CUTS LONMIN PRICE TARGET TO 190 (250) PENCE - 'NEUTRAL'
----------
UBS CUTS POLYMETAL PRICE TARGET TO 500 (550) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS BARRATT DEVELOPMENTS PRICE TARGET TO 499 (530) PENCE - 'BUY'
----------
GOLDMAN RAISES BERKELEY GROUP PRICE TARGET TO 2871 (2870) PENCE - 'NEUTRAL'
----------
Numis Upgrades Bank Of Georgia To Buy From Hold, Price Target 2,708 pence
----------
MAIN MARKET AND AIM
----------
GOLDMAN CUTS ASOS PRICE TARGET TO 3000 (4300) PENCE - 'BUY'
----------
GOLDMAN CUTS SHANKS GROUP PRICE TARGET TO 109 (128) PENCE - 'BUY'
----------
Liberum Raises Game Digital Price Target To 265p From 350p, Buy
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.